uploads/2018/06/Chart-07-3-1.jpg

Eli Lilly’s Oncology Product Portfolio

By

Updated

Oncology products

Eli Lilly’s (LLY) oncology products portfolio includes Erbitux, Cyramza, Lartruvo, Alimta, and the recently released Verzenio. The company’s oncology products reported revenue growth during the first quarter. This growth followed the strong sales of Alimta, Lartruvo, Cyramza, and Verzenio. This growth was partially offset by lower sales of Erbitux during the quarter. The chart below compares the revenues for key oncology products since the first quarter of 2017.

Article continues below advertisement

Alimta

Alimta reported revenues of ~$500.0 million during the first quarter, representing 2.0% growth compared to ~$490.0 million during the first quarter of 2017. This growth was driven by strong sales in the US markets and partially offset by lower sales from its international markets. 

The sales from the US markets rose 8.0% to $245.3 million. Sales from its international markets fell 3.0% to $254.3 million during the quarter.

Cyramza

Cyramza reported revenues of ~$184.0 million during the first quarter, representing 7.0% growth compared to revenues of ~$171.0 million during the first quarter of 2017. This growth was driven by an increase in its US and international sales. 

Cyramza’s sales in the US markets rose 3.0% to $68.3 million. Sales from its international markets rose ~10.0% to $115.3 million during the quarter.

Article continues below advertisement

Erbitux

Erbitux reported revenues of ~$150.0 million during the first quarter, a 3.0% decline compared to its revenues of ~$154.0 million in the first quarter of 2017. This decline was driven by lower sales from the US markets, partially offset by strong sales in the international markets during the quarter.

Other oncology products

Previously in this series, we discussed the performance of Lartruvo and Verzenio, Eli Lilly’s other oncology products.

The iShares Russell Top 200 Growth ETF (IWY) holds 0.8% of its total investments in Eli Lilly (LLY), 1.5% in AbbVie (ABBV), 0.6% in Gilead Sciences (GILD), and 0.6% in Biogen (BIIB).

Advertisement

More From Market Realist